
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Varoglutamstat
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Vivoryon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2022
Lead Product(s) : Varoglutamstat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Vivoryon Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Puerarin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms
Details : Kudzu Root Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Puerarin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Recipient : Bone Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JTA-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2020
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Recipient : Bone Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : KeyBioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Details : KBP-042 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 26, 2017
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : KeyBioscience
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sprifermin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sprifermin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 08, 2013
Lead Product(s) : Sprifermin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Recipient : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abaloparatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoporosis, Postmenopausal.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 29, 2012
Lead Product(s) : Abaloparatide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Recipient : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
